Recombinant Bivalent(GI.1/GII.4) norovirus vaccine (National Vaccine and Serum Institute)

评价6月龄~59岁健康人群接种不同剂量重组诺如病毒双价（GI.1/GII.4）疫苗（汉逊酵母）全程免疫后14天的免疫原性。进一步评价在6月龄~59岁健康人群接种不同剂量试验疫苗的安全性；探索试验疫苗在6月龄~59岁健康人群中的免疫持久性。

A total of 450 subjects were enrolled, divided into four age groups, including 18-59 years, 6-17 years, 3-5 years, and 6-35 months. There are three types of the test vaccine component in each age group. A total of 30 people in each dose group were vaccinated with the test vaccine or placebo 1 or placebo 2, respectively, in a ratio of 3: 1: 1.
The 18-59-year-old, 6-17-year-old, and 3-5-year-old age groups were vaccinated 2 times at a time interval of 28 days. The 6-35 month age group is divided into two groups, Group 1 is inoculated with 2 doses interval of 28 days each, and Group 2 is inoculated with 3 doses interval of 28 days.